Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Author(s): Patrick M. Forde, M.D.¹; Jonathan D. Spicer, M.D.²; Mariano Provencio, M.D.³; Tetsuya Mitsudomi, M.D.⁴; Mark M. Awad, M.D.⁵; Changli Wang, M.D.⁶; Shun Lu, M.D.⁷; Enriqueta Felip, M.D.⁸; Scott J. Swanson, M.D.⁹; Julie R. Brahmer, M.D.¹⁰; Keith Kerr, M.D.¹¹; Janis M. Taube, M.D.¹²; Tudor-Eliade Ciuleanu, M.D.¹³; Fumihiro Tanaka, M.D.¹⁴; Gene B. Saylors, M.D.¹⁵; Ke-Neng Chen, M.D.¹⁶; Hiroyuki Ito, M.D.¹⁷; Moishe Liberman, M.D.¹⁸; Claudio Martin, M.D.¹⁹; Stephen Broderick, M.D.²⁰; Lily Wang, M.D.²¹; Junliang Cai, M.D.²²; Quyen Duong, M.D.²³; Stephanie Meadows-Shropshire, M.D.²⁴; Joseph Fiore, M.D.²⁵; Sumeena Bhatia, M.D.²⁶; Nicolas Girard, M.D.²⁷;

Source: DOI: 10.1056/NEJMoa

Dr. Maen Hussein's Thoughts

There was a 28% reduction in mortality. Patients who achieved a complete response (CR) or clearance of circulating tumor DNA (ctDNA) also experienced better outcomes.

BACKGROUND

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial. Data are needed on overall survival.

METHODS

In this open-label, phase 3 trial, patients with stage IB to IIIA resectable NSCLC were randomly assigned to receive nivolumab plus chemotherapy or chemotherapy alone for three cycles, followed by surgery. The primary end points were event-free survival and pathological complete response. Here, we report the results of the planned analysis of overall survival. Research Summary Overall Survival with Neoadjuvant Nivolumab in NSCLC

RESULTS

A total of 358 patients were concurrently assigned to receive nivolumab plus chemotherapy (179 patients) or chemotherapy alone (179 patients). The final analysis of overall survival significantly favored neoadjuvant nivolumab plus chemotherapy over chemotherapy (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.523 to 0.998; P=0.048). At a median follow-up of 68.4 months, the 5-year overall survival was 65.4% with nivolumab plus chemotherapy and 55.0% with chemotherapy alone, with consistency across most subgroups. In exploratory analyses, the 5-year overall survival in the nivolumab-plus-chemotherapy group was 95.3% (95% CI, 82.7 to 98.8) among the patients with a pathological complete response and 55.7% (95% CI, 46.9 to 63.7) among those without such a response; survival was 75.0% among the patients with presurgery clearance of circulating tumor DNA (ctDNA) and 52.6% among those without such clearance. No new safety signals were observed.

CONCLUSIONS

Three cycles of neoadjuvant nivolumab plus chemotherapy significantly improved overall survival among patients with resectable NSCLC as compared with chemotherapy alone. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.)

Author Affiliations

¹Trinity St. James’s Cancer Institute, Trinity College Dublin, Dublin; ²McGill University Health Centre, Montreal; ³Hospital Universitario Puerta de Hierro, Madrid; ⁴Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, Japan; ⁵Memorial Sloan Kettering Cancer Center, New York; ⁶Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; ⁷Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; ⁸Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Universitat Autònoma Barcelona, Barcelona; ⁹Brigham and Women’s Hospital, Boston; ¹⁰Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore; ¹¹Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ¹²Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore; ¹³Institutul Oncologic Prof. Dr. Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania; ¹⁴University of Occupational and Environmental Health, Kitakyushu, Japan; ¹⁵Charleston Oncology, Charleston, SC; ¹⁶State Key Laboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, Beijing; ¹⁷Kanagawa Cancer Center, Yokohama, Japan; ¹⁸Centre Hospitalier de l’Université de Montréal, Montreal; ¹⁹Instituto Alexander Fleming, Buenos Aires; ²⁰Bristol Myers Squibb, Princeton, NJ; ²¹Institut du Thorax Curie-Montsouris, Institut Curie, Paris

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a median progression-free survival (PFS) of 5.5 months compared to 3.8 months with docetaxel in patients with KRAS G12C-mutated tumors. Treatment-related adverse events occurred in 47% of patients receiving Adagrasib and 46% in the docetaxel group. In my experience, Adagrasib is also more tolerable, making it a favorable option for this patient population.

Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Another option for HER-2 lung cancer patients. 71% had an objective response with a duration of 14.1 months and progression-free survival (PFS) of 12.4 months. Grade 3 adverse events were observed in 17% of patients. Some patients had been previously treated with HER-2 ADC therapy.

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer

The phase II trial of neoadjuvant PD-1/PD-L1 blockade plus chemotherapy in borderline resectable and unresectable stage III NSCLC showed a significant improvement in event-free survival (EFS) with the combination (24.1 vs 10.6 months) compared to chemotherapy alone, with a hazard ratio (HR) of 0.62. Major pathological response rates were higher with immunotherapy (44.7% vs 22.3%), and no new safety signals were noted. The regimen improved surgical resection rates (68% vs 52%) without increasing perioperative complications. This validates chemoIO in the neoadjuvant setting particularly in whom we wish to pursue resection or avoid chemoradiation. It would be great to see this compared to chemoradiation followed by immunotherapy rather than chemotherapy alone.

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Results showed the median event-free survival (EFS) was 54.8 months with nivolumab plus ipilimumab vs 20.9 months with chemotherapy. Three-year EFS rates were 56% vs 44%. Three-year overall survival (OS) rates were 73% vs 61% pathologic complete response rates were 20.4% vs 4.6%. This was three cycles of nivolumab and one dose of ipilimumab vs chemotherapy.

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Dato showed a confirmed overall response rate (ORR) of 42.7% with a complete response (CR) of 4.3%. The median duration of response was 7.0 months, with a disease control rate of 86.3% and a median overall survival (OS) of 15.6 months. This could be another option for EGFR mutant patients who had multiple lines of therapy.